Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.
Brown TM, Holland J, Bokowy KL, Horblyuk R. Can transformational programs aimed at improving hospital management, leadership, and productivity systems affect financial performance? J Hospital Admin. 2013 Jul 30;2(4):111-9.
DiBenedetti DB, Nguyen D, Zografos L, Ziemiecki R, Zhou X. Prevalence, incidence, and treatments of Dupuytren's disease in the United States: results from a population-based study. Hand (N Y). 2011 Jun 1;6(2):149-58.